Cargando…
Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A Randomised Controlled Trial
BACKGROUND: This was the first study to investigate the reactogenicity and immunogenicity of heterologous or fractional second dose COVID-19 vaccine regimens in adolescents. METHODS: A phase II, single-blind, multi-centre, randomised-controlled trial recruited across seven UK sites from September to...
Autores principales: | Kelly, Eimear, Greenland, Melanie, de Whalley, Philip C S, Aley, Parvinder K, Plested, Emma L, Singh, Nisha, Koleva, Stanislava, Tonner, Sharon, Macaulay, Grace C, Read, Robert C, Ramsay, Mary, Cameron, J Claire, Turner, David P J, Heath, Paul T, Bernatoniene, Jolanta, Connor, Philip, Cathie, Katrina, Faust, Saul N, Banerjee, Indraneel, Cantrell, Liberty, Mujadidi, Yama F, Belhadef, Hanane Trari, Clutterbuck, Elizabeth A, Anslow, Rachel, Valliji, Zara, James, Tim, Hallis, Bassam, Otter, Ashley David, Lambe, Teresa, Nguyen-Van-Tam, Jonathan S, Minassian, Angela M, Liu, Xinxue, Snape, Matthew D |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd on behalf of The British Infection Association.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275659/ https://www.ncbi.nlm.nih.gov/pubmed/37331429 http://dx.doi.org/10.1016/j.jinf.2023.06.007 |
Ejemplares similares
-
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial
por: Shaw, Robert H, et al.
Publicado: (2022) -
Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
por: Shaw, Robert H, et al.
Publicado: (2021) -
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6–17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial
por: Li, Grace, et al.
Publicado: (2022) -
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
por: Flaxman, Amy, et al.
Publicado: (2021) -
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
por: Liu, Xinxue, et al.
Publicado: (2021)